Compugen predictive discovery capabilities for cancer immunotherapy are focused on novel B7/CD28 like immune checkpoints and other immunomodulatory protein candidates.
Immune checkpoints are negative regulators of the immune system, that play critical roles in maintaining self-tolerance, preventing autoimmunity and protecting tissues from immune collateral damage. These immune checkpoints are often "hijacked" by tumors to restrain the ability of the immune system to mount an effective anti-tumor response. Blocking immune checkpoints is thus a promising approach for activating anti-tumor immunity
Immunomodulatory proteins are proteins capable of modifying or regulating one or more immune functions. Immune checkpoints, including inhibitory receptors and ligands, are one type of immune modulators.
The immune system is programmed to avoid attacking the body’s own cells and tissues in a mechanism known as self-tolerance. The negative regulators of the immune system, known as immune checkpoints, play a critical role in the maintenance of self-tolerance. In autoimmune diseases self-tolerance is compromised and the immune system mistakenly attacks the body’s own tissues. Autoimmune diseases are characterized by hyperactive immune responses that target self-antigens, leading to chronic inflammation and targeted destruction of tissues and organs. An autoimmune disease can be limited to a single organ or may affect multiple organs and tissues. Autoimmune diseases affect millions worldwide, who may suffer from symptoms ranging from mild rashes to life-threatening conditions when major body organs are affected. Autoimmune diseases are a leading cause of disability and death.READ MORE